TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03994341

Intervention type: DIAGNOSTIC_TEST
Intervention: A FLIR Thermovision a320M thermal IR camera
Description: 1. Clothing removed if necessary~2. ECG leads, temperature probes, or transcutaneous monitors will be relocated for abdominal imaging.~3. Axillary temperature prior to starting the thermographic imaging.~4. Baby's mattress slid out of the isolette and warming bed will be turned off for no more than 60 seconds. This step is necessary since infrared radiation does not pass through the Plexiglas walls of an isolette and the infant's skin surface needs to cool off slightly.~5. After surface cooling, thermal imaging will be recorded for \~60 sec to allow for the infrared radiation naturally emitted by the subject's body to be recorded by the infrared camera. The timestamp corresponding to the removal of the heat source will be noted, to indicate the start of the cooling of the abdomen.~6. After \~60 seconds of image recording, the recording will stop, the mattress pushed back into isolette.~7. Axillary temperature to ensure temperature stability, any clothes will be put back on.

Intervention type: DIAGNOSTIC_TEST
Intervention: A FLIR Thermovision a320M thermal IR camera
Description: 1. Clothing removed if necessary~2. ECG leads, temperature probes, or transcutaneous monitors will be relocated for abdominal imaging.~3. Axillary temperature prior to starting the thermographic imaging.~4. Baby's mattress slid out of the isolette and warming bed will be turned off for no more than 60 seconds. This step is necessary since infrared radiation does not pass through the Plexiglas walls of an isolette and the infant's skin surface needs to cool off slightly.~5. After surface cooling, thermal imaging will be recorded for \~60 sec to allow for the infrared radiation naturally emitted by the subject's body to be recorded by the infrared camera. The timestamp corresponding to the removal of the heat source will be noted, to indicate the start of the cooling of the abdomen.~6. After \~60 seconds of image recording, the recording will stop, the mattress pushed back into isolette.~7. Axillary temperature to ensure temperature stability, any clothes will be put back on.
Study: NCT02046941

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech Production Treatment
Description: This treatment employs a response-contingent hierarchy made up of verbal modeling/repetition, graphic cueing, integral stimulation, and articulatory placement instruction.
Study: NCT01435798

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dextromethorphan
Description: 0, 25, 50 and 100% of maximum tolerated dose, each administered over a 4 week period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: 0, 25, 50 and 100% of maximum tolerated dose, each administered over a 4 week period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: 0, 25, 50 and 100% of maximum tolerated dose, each administered over a 4 week period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: 0, 25, 50 and 100% of maximum tolerated dose, each administered over a 4 week period
Study: NCT01225159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TGC
Description: TGC used hyperinsulinaemic normoglycaemic clamp with modified glucose-insulin-potassium to control blood sugar. The insulin (HumulinTM R, Lilly pharma, Germany) was diluted with normal saline to the concentration 1 IU. mL-1 and was infused continuously throughout the operations at a fixed rate of 0.3 IU. kg-1.h-1 but the maximal rate was 20 IU/ h. A separate mixture of glucose 25% (A.N.B Laboratories, Thailand) 50 mL, potassium chloride (Nida pharma, Thailand) 20 mEq and magnesium sulfate (Atlantic, Thailand) 2 gm was infused at 0.75 mL.kg-1.h-1 and was adjusted to maintain blood glucose levels 80-150 mg/dL.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Conventional glycaemic control
Description: Conventional glycaemic control aims to control blood sugar less than 250 mg%. Insulin was given bolusly if the blood sugar more than 250 mg%.
Study: NCT00913783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomipramine Hydrochloride 25 mg Capsules (Geneva Pharmaceuticals)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anafranil Clomipramine Hydrochloride 25 mg Capsules (Basel)
Study: NCT01603342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel
Description: Following a baseline punch biopsy, all subjects will then receive oral clopidogrel (Plavix®) over a period of approximately 3 to 4 days. Once the subject has successfully had 3 days of clopidogrel dosing, a second biopsy (B1) will be performed

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Following a baseline punch biopsy, all subjects will then receive oral placebo over a period of approximately 3 to 4 days. Once the subject has successfully had 3 days of clopidogrel dosing, a second biopsy will be performed
Study: NCT02929706

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Pre-genotype NUDT15 and optimize azathioprine dosage
Description: Pre-genotype NUDT15 and optimize azathioprine dosage.The wild type use azathioprine(Imuran，2-2.5mg/kg/d),the CT genotype use half dose of azathioprine（Imuran，1-1.5mg/kg/d).The TT genotype avoid use of azathioprine.
Study: NCT02206945

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: neurofeedback
Description: Subject provided with feedback of activity in target brain area in the form of a line graph. Cued to try to make the line go up at certain times and down at other times.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: control feedback
Description: Subject provided with a control/placebo type of feedback in the form of a line graph. Cued to try to make the line go up at certain times and down at other times.
Study: NCT03756064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: Pyrotinib: 400mg orally daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab:8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 6 cycles;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab:8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 6 cycles;

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel: 75mg/m2 for a total of 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel: 75mg/m2 for a total of 6 cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin: AUC=5 for a total of 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin: AUC=5 for a total of 6 cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo Oral Tablet: 400mg orally daily
Study: NCT04024514

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low dose CT contrast media
Description: CT contrast media (Ioversol 320mgI/kg) is administrated at a dose of 300mgI/kg in low dose group

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard dose CT contrast media
Description: CT contrast media (Ioversol 350mgI/kg) is administrated at a dose of 525mgI/kg in standard dose group.
Study: NCT04322916

Intervention type: DEVICE
Intervention: RM Pressfit vitamys
Description: Implantation of a RM Pressfit vitamys hip cup
Study: NCT04019249

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Weight Coaching
Description: Healthy Weight Coaching is a 52 week long web-based weight loss program consisting of weekly modules, exercises, peer support, and one-on-one coaching. It encompasses themes such as diet, physical activity, coping with stress, sleep, and general health.
Study: NCT00335374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pardoprunox
Description: 12 -42 mg
Study: NCT02388113

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: accumulated exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: traditional exercise
Study: NCT02568878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate
Study: NCT03618836

Intervention type: OTHER
Intervention: Microbiological and biological patterns on vaginal samples
Description: To compare the microbiological and biological patterns between groups

Intervention type: OTHER
Intervention: Microbiological and biological patterns on vaginal samples
Description: To compare the microbiological and biological patterns between groups
Study: NCT03598725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coagulation Factor VIII
Description: Domastic plasma derived factor FVIII (with intermidiate vWF) 50IU/kg every other day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 2mg/kg every day for 4 weeks then typering in 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375mg/Square meter for consecutive 4 months
Study: NCT03803553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI Protocol
Description: FOLFIRI cycle will be two weeks (14 days) long, with FOLFIRI administered on Days 1-3. Participants will receive up to 12 two-week cycles (for a total of 24 weeks) of FOLFIRI chemotherapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ACTIVE SURVEILLANCE
Description: Will be followed with observation and monitoring with imaging, tumor markers, and ctDNA collections

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ACTIVE SURVEILLANCE
Description: Will be followed with observation and monitoring with imaging, tumor markers, and ctDNA collections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Protocol
Description: Nivolumab cycle will be four weeks (28 days) long, with Nivolumab administered on day 1. Participants will receive up to 12 four-week cycles (for a total of 48 weeks) of Nivolumab treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib/Binimetinib/Cetuximab Protocol
Description: Encorafenib/Binimetinib will be taken orally every day and Cetuximab will be administered intravenously on day 1 of each cycle. Cycles are 14 days long. Participants will receive up to 12 two-week cycles (for a total of 24 weeks) of Encorafenib/Binimetinib/Cetuximab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab + Pertuzumab
Description: Trastuzumab (Herceptin) is received by intravenous administration and Pertuzumab is received intravenously by infusion on Day 1 of each cycle. Cycles are 21 days long. Participants will receive up to 8 cycles of Trastuzumab and Pertuzumab.
Study: NCT03280108

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof IQ PanOptix Multifocal IOL
Description: AcrySof IQ PanOptix Multifocal IOL Model TFNT00 for near, intermediate, and distance vision

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AcrySof Monofocal IOL
Description: AcrySof Monofocal IOL Model SN60AT for single vision
Study: NCT01512914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 30 mg
Description: preoperative instillation of saline 20 ml, nebulization of ropivacaine 1% 3 ml (30 mg) before surgery and nebulization of saline 3 ml after surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 30 mg
Description: preoperative instillation of saline 20 ml, preoperative nebulization of saline 3 ml and nebulization of ropivacaine 1% 3 ml (30 mg) after surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 100 mg
Description: preoperative instillation of ropivacaine 0,5% 20 ml (100 mg) and nebulization of saline 3 ml before and after surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: preoperative instillation of saline 20 ml and nebulization of saline before and after surgery
Study: NCT04006236

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Infant Formula
Description: Feed Ad Libitum

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Infant Formula
Description: Feed Ad Libitum
Study: NCT02801409

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia alone
Description: General anesthesia is performed during surgery; patient-controlled intravenous analgesia is provided after surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined epidural-general anesthesia
Description: Combined epidural-general anesthesia is performed during surgery; patient-controlled epidural analgesia is provided after surgery.
Study: NCT03800485

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IMT
Description: A training protocol of the inspiratory muscles that goes from the 15% of the maximal inspiratory muscle preassure until the 60% of the maximal inspiratory muscle preassure during 8 weeks

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: IMT
Description: A training protocol of the inspiratory muscles that goes from the 15% of the maximal inspiratory muscle preassure until the 60% of the maximal inspiratory muscle preassure during 8 weeks
Study: NCT00604513

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ready. Set. ACTION! Protocol
Description: The intervention included three components: theater sessions; booster sessions; and family outreach. After-school theater sessions were conducted in the fall in the intervention schools. Sessions included: a check-in about changes made over the past week; healthy snacks; a movement component that involved fun and easy activities; and creating/education. Children at intervention schools participated in weekly after-school booster sessions in the winter to further address the behavioral messages addressed during the intervention. Throughout the program, weekly Fun \& Fitness packs were sent home to families that included a healthy food with a simple recipe using that food or fitness incentives for the family. There were also two family events: a theater performance, and a reception.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: The control condition also participated in a theater-based intervention that addressed a health topic unrelated to weight, hand-washing and overall personal hygiene.
Study: NCT04007146

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transcutaneous oxymetry measurement
Description: Transcutaneous oxymetry measurement with transient hyperoxia period (2 periods of 30seconds at 60% of oxygen)
Study: NCT01187407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRI
Description: Participants should have been on their SSRI for at least 6 weeks prior and were to continue on their stable dose throughout the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRI
Description: Participants should have been on their SSRI for at least 6 weeks prior and were to continue on their stable dose throughout the study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SSRI
Description: Participants should have been on their SSRI for at least 6 weeks prior and were to continue on their stable dose throughout the study
Study: NCT00874497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tetomilast
Description: Oral tetomilast 25 mg once daily for 2 weeks followed by 50 mg once daily for 2 years.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo for 104 weeks (2 years)
Study: NCT03269695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06687234
Description: SC QW

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC QW
Study: NCT01344499

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carbon dioxide
Description: standard pneumoperitoneum with 100% CO2

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carbon dioxide
Description: standard pneumoperitoneum with 100% CO2

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: full conditioning
Description: Pneumoperitoneum with CO2 + 4% of oxygen + 10% nitrous oxide + 100% RH + T° 32°C

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: full conditioning
Description: Pneumoperitoneum with CO2 + 4% of oxygen + 10% nitrous oxide + 100% RH + T° 32°C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adept
Description: instillation of 1 liter of fluid at the end of laparoscopy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer Lactate
Description: instillation of 1 liter of fluid at the end of laparoscopy
Study: NCT04202016

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piezocision Surgery
Description: After a surgical cut using #15 surgical blade 2-3 mm distal to the canine a pizocision using piezo-surgery device is made.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piezocision Surgery
Description: After a surgical cut using #15 surgical blade 2-3 mm distal to the canine a pizocision using piezo-surgery device is made.
Study: NCT01728688

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PBSC transplantation
Description: PBSCs were mobilized with recombinant human G-CSF at 5-10ug/kg/d for three days. then PBSCs were collected by means of apheresis. The collected PBSCs were infused into participant via hepatic artery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional treatment
Description: Participants will receive conventional treatment and antiviral treatment.
Study: NCT00857233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: 20 mg oral tablets once daily
Study: NCT02276209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasotraline
Description: Dasotraline 4 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasotraline
Description: Dasotraline 6 mg once daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily
Study: NCT02010398

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cross-Training healthy subjects
Description: The phase of intervention will consist of a 6-week cross-training of the stronger limb employing an isokinetic contraction regimen at maximal intensity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cross-Training multiple sclerosis
Description: The phase of intervention will consist of a 6-week cross-training of the less-impaired limb employing an isokinetic contraction regimen at maximal intensity.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard-training multiple sclerosis
Description: The phase of intervention will consist of a 6-week standard strength training of the more-impaired limb employing an isokinetic contraction regimen performed at maximal intensity.
Study: NCT03458923

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Sodium 0.1 ml containing 500µg
Description: 15 eyes will receive intravitreal 0.1 ml containing 500µg of Diclofenac Sodium monthly for three months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab 0.5 mg Solution for Injection
Description: 15 eyes will receive intravitreal 0.5 mg of Ranibizumab monthly for three months
Study: NCT02418741

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neck flexion
Description: Patient's neck was flexed using a 4 cm or 8 cm height of pillow
Study: NCT03447652

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Band Ankle Rehabilitation
Description: Resistance Band - uses a tension band to provide resistance during ankle motion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biomechanical Ankle Platform System Rehabilitation
Description: Biomechanical Ankle Platform System Board Group - uses different levels of half spheres to increase the amount of motion allowed at the ankle.
Study: NCT01603771

Intervention type: OTHER
Intervention: Blood Oxygen Level Dependent (BOLD) functional magnetic imaging (fMRI)
Description: All participants complete MRI scans at baseline and at the end of month 6. Scanning sessions last approximately 30 minutes each and consist of two components: (1) High resolution T1-weighted MPRAGE anatomic images to provide detailed anatomy and maximum gray-white matter contrast for images and to allow any estimate of regional or whole-brain volume, and (2) Resting BOLD functional images to allow assessment of the functional connectivity in large scale networks.

Intervention type: OTHER
Intervention: Blood Oxygen Level Dependent (BOLD) functional magnetic imaging (fMRI)
Description: All participants complete MRI scans at baseline and at the end of month 6. Scanning sessions last approximately 30 minutes each and consist of two components: (1) High resolution T1-weighted MPRAGE anatomic images to provide detailed anatomy and maximum gray-white matter contrast for images and to allow any estimate of regional or whole-brain volume, and (2) Resting BOLD functional images to allow assessment of the functional connectivity in large scale networks.
Study: NCT02625753

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Codeine
Description: Patients submitted to photorefractive keratectomy received codeine 50mg plus paracetamol 500mg every 6h for 72h after the procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol
Description: Patients submitted to photorefractive keratectomy received codeine 50mg plus paracetamol 500mg every 6h for 72h after the procedure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patients submmitted to photorefractive keratectomy received placebo, in the form of a pill of similar appearance to the comparator, every 6h for 72h after the